Insulet Corporation (PODD)
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.
Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Insulet's stock has surged over 50% in six months due to strong Q3 earnings and expanded market potential with Omnipod 5's approval for Type 2 diabetes. Despite impressive growth, high market expectations and potential competition from giants like Medtronic and Abbott pose significant risks to Insulet's future performance. The company's financials are robust, with rising revenues, margins, and a strong cash position, but the stock's high valuation demands continued exceptional growth.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up
Insulet's third-quarter performance benefits from the continued high demand for Omnipod 5.
Insulet CEO on earnings, GLP-1 and election impact
Jim Hollingshead, Insulet CEO, joins 'Closing Bell: Overtime' to discuss the Insulet earnings, Apple blood sugar testing app and more.
Buy, Sell, Or Hold Insulet (PODD) Stock?
Insulet stock (NASDAQ: PODD) surged nearly 10% on Friday, November 8, after the company posted an upbeat Q3 and raised its sales outlook. It reported sales of $544 million and adjusted earnings of $0.90 per share, compared to the consensus estimates of $518 million and $0.77, respectively.
Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript
Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript
Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insulet (PODD) Q3 Earnings and Revenues Top Estimates
Insulet (PODD) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.71 per share a year ago.
Insulet raises annual revenue forecast on strong demand for insulin pumps
Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.
Insulet Stock Gains From Expansion Strategies, Innovation
PODD continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign.
Stay Ahead of the Game With Insulet (PODD) Q3 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Insulet (PODD) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
